A Phase 3 interventional study of Nivolumab and Ipilimumab in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 78 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing ipilimumab in Carcinoma, Renal Cell — 5 open to participants now, 9 under way, 2 of them phase 3. Ipilimumab · Carcinoma, Renal Cell.
Among the 29 studies testing ipilimumab in Carcinoma, Renal Cell, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2019, is one of 4 in phase 3, and was the 17th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →5 of the 29 studies testing ipilimumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
West China Hospital · Sites in China
Ages 14+
By country, each count listing its studies:
Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, ipilimumab is the treatment under test here. Read study by study →
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 21 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 437 is above the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 72 across the 28 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb: 5 open now, 8 under way, 2 of them phase 3. Of 32 finished, 16 (50%) have results posted.
Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 3, and was the 28th registered.
Bristol-Myers Squibb’s Carcinoma, Renal Cell studies by the year they started, since 2003.
5 of the studies testing ipilimumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT02496208National Cancer Institute (NCI)Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | 2027-07-30 |
| NCT05361720Vanderbilt-Ingram Cancer CenterGenetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 29 studies testing ipilimumab in Carcinoma, Renal Cell, from their registry updates:
Among Bristol-Myers Squibb’s 42 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Nivolumab · Biological: Ipilimumab
Other: Ipilimumab placebo
Specified dose on specified days
Also known as: Opdivo
Specified dose on specified days
Also known as: Yervoy
Specified dose on specified days
Progression free survival (PFS) by blinded independent central review (BICR)
Time frame: Up to 34 months
Objective response rate (ORR) by BICR
Time frame: Up to 23 months
Overall survival (OS)
Time frame: Up to 4 years
Overall response rate (ORR) by investigator
Time frame: Up to 4 years
Disease control rate (DCR) by investigator
Time frame: Up to 4 years
Duration of response (DoR) by investigator
Time frame: Up to 4 years
Time to objective response (TTR) by investigator
Time frame: Up to 4 years
Progression Free Survival (PFS) by investigator
Time frame: Up to 4 years
Progression free survival secondary objective (PFS2) by investigator
Time frame: Up to 4 years
Disease control rate (DCR) by BICR
Time frame: Up to 4 years
Duration of response (DoR) by BICR
Time frame: Up to 4 years
Time to objective response (TTR) by BICR
Time frame: Up to 4 years
Incidence of Adverse Events (AEs)
Time frame: Up to 4 years
Incidence of drug-related AEs
Time frame: Up to 4 years
Incidence of Severe Adverse Events (SAEs)
Time frame: Up to 4 years
Incidence of drug-related SAEs
Time frame: Up to 4 years
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Time frame: Up to 4 years
Incidence of clinically significant changes in clinical laboratory results: Coagulation tests
Time frame: Up to 4 years
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Time frame: Up to 4 years
Incidence of clinically significant changes in clinical laboratory results: Serology tests
Time frame: Up to 4 years
PFS based on gene expression (GEP) signatures
Time frame: Up to 4 years
Objective response rate (ORR) based on GEP signatures
Time frame: Up to 4 years
OS based on GEP signatures
Time frame: Up to 4 years
OS based on programmed cell death protein ligand-1 (PD-L1) expression
Time frame: Up to 4 years
ORR by BICR based on PD-L1 expression
Time frame: Up to 4 years
PFS by BICR based on PD-L1 expression
Time frame: Up to 4 years
Plan to share: Yes — Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html
Started Jun 2019 (actual). Primary completion is estimated for Mar 2027, 92 months after the start.
Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's planned 92 months is above that.
Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ipilimumab